HopeStage
Back to all studies
RecruitingNCT04226898

Study of a synbiotic supplement in schizophrenia

About this titleRead the official source — NCT04226898
Placebo comparisonAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
BatlimoreSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 21, 2022
Recruitment status
Recruiting
Enrollment listed in the registry
68
Sponsor
Sheppard Pratt Health System
Sponsor type
Unknown or unclear
Study type
Biological
Intervention type
Biological
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04226898
Official title
Show the full official title

A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal Inflammation

Recruitment & locations

Currently recruiting

Batlimore

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sheppard Pratt Health System.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies